It's official: Amgen is appealing last week's ruling in a fight over biosimilar Neupogen. The California-based biotech, aiming to protect its $1.2 billion branded drug, wants to bar Novartis from launching its biosimilar version, Zarxio.
Amgen's deCODE Genetics has published a series of papers that hint at how the the Big Biotech could begin to recoup the $415 million it paid for the population-scale sequencing pioneer. For Amgen, the meat of the project lies in the discovery of 8,000 human knockouts, people who lack a working version of one of 1,171 genes.
What's better than a new drug launch? A launch destined for greatness, of course. For sales and marketing teams, that's about as much job security as you can get.
Dako is extending its collaboration with pharma giant Amgen to develop companion diagnostic products for drug development and research. Neither side is revealing financial details, but Dako, now an Agilent company, said the deal will focus on personalized medicine and tests that pair patients with suitable treatments.
Japan's Astellas Pharma has filed with Japan's Pharmaceutical and Medical Devices Agency for approval of PCSK9 inhibitor evolocumab for high cholesterol under the Amgen Astellas BioPharma joint venture.
Novartis made history this month with the first FDA approval of a biosimilar, and now a judge's ruling has cleared the way for its launch. The drug, Zarxio, is a copy of Amgen's blockbuster Neupogen, which is designed to boost white blood cell counts.
Novartis CEO Joe Jimenez was a bit dismissive about the immediate impact of biosimilars when his company became the first to get one approved in the U.S. But Amgen didn't see the biosimilar of its blockbuster Neupogen in quite the same light and tried to stop its release. Unfortunately for the company, a federal judge denied Amgen's request for a temporary injunction.
A new generation of cardiovascular drugs has proved itself capable of lowering bad cholesterol across dozens of Phase III trials, but many physicians are holding out to see whether doing so can meaningfully improve patients' lives. In an early peek at some long-term data, one such injected therapy from Amgen halved the risk of major cardiovascular problems after one year of treatment, bolstering the case for the whole class of drugs.
Amgen Pharmaceuticals is doing what companies do when they snap up a smaller rival: layoffs and a shutdown. But in this case, Amgen is doing it 19 months after the fact. The biotech giant will cut loose 300 staffers at its oncology subsidiary Onyx Pharmaceuticals and shut down Onyx's building in San Francisco.
Days after Onyx Pharmaceuticals' banner drug came through in a big Phase III trial, Amgen is laying off about 40% of the subsidiary's staff, shedding roughly 300 workers amid widespread cuts around the industry.